Neurochase Ltd. filed a patent for a septum-sealed transcutaneous, fluid-transferring device through which repeated access for the removal or delivery of fluid to the central nervous system (CNS) can be gained.
Etern Biopharma (Shanghai) Co. Ltd. has described bicyclic heteroaryl compounds acting as transcriptional coactivator YAP1 and/or TAZ/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer, fibrosis and cardiovascular disorders.
Vertex Pharmaceuticals Inc. has divulged cystic fibrosis transmembrane conductance regulator (CFTR) modulators reported to be useful for the treatment of cystic fibrosis.
Beigene Ltd. has identified heterocyclic compounds acting as E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of hematologic cancer and glioblastoma.
Shenzhen Forward Pharmaceuticals Co. Ltd. has synthesized quinazoline derivatives acting as GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer, particularly lung cancer.
Researchers at the Georgia Institute of Technology (Georgia Tech) in Atlanta have developed melting microneedle patches comprising a drug dissolved or dispersed in a wax.
Madrigal Pharmaceuticals Inc. has divulged thyroid hormone receptor β (THR-β) agonists reported to be useful for the treatment of familial hypercholesterolemia, hyperlipidemia, hypertriglyceridemia and nonalcoholic steatohepatitis.
Gasherbrum Bio Inc. has identified glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes, dyslipidemia, hyperglycemia, hypertension, obesity, stroke, myocardial infarction and gout, among others.
RSS
